Optimal management of breast cancer in the elderly patient: current perspectives.

Clin Interv Aging · 2015 · PMC4293298 · PMID 25609933

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significanceP =0.075so close (0.05 < p ≤ 0.1)

In the second study, 38 comparing epirubicin plus cyclophosphamide for four cycles versus exemestane for 24 weeks, a greater clinical response rate with chemotherapy versus hormone therapy was found (66% versus 48%), but this did not reach statistical significance ( P =0.075).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.